SOF, 7 (11%) SOF/ledipasvir. Main (>10%) ART regimens were: 11 (18%) dolutegravir/tenofovir/emtricitabine, 9 (15%) raltegravir/ tenofovir/emtricitabine. Thirty-seven (60%) pts completed anti-HCV treatment (Table 1): 36/ 62 (58%) achieved HCV-RNA <12 UI/mL by week 4 and 37/37 (100%) at the end of treatment. Thirty-six (58%) pts experienced ≥1 grade 3–4 adverse event (Table 1); the most common AEs were: anaemia (17%), total bilirubin elevations (29%), bacterial infections (3%). During anti- HCV treatment, 29 (47%) pts reduced RBV dosage, 13 (21%) required erythropoietin. Up to date, no discontinuation of DAA regimens occurred. HIV immuno-virological outcomes are shown in Table 1: 2 viral blips and 1 virological failure (2 consecutive HIV-RNA > 50 cps/ mL) were observed during follow-up. No AIDS defining events occurred. Conclusions: DAAs-associated with RBV weight-based were effective, generally well tolerated and also with favorable HIV immuno-virological outcomes suggesting that the use of DAA regimens plus RBV can be safely used in cirrhotic pts co-infected with HIV. SAT-206 DIFFERENCES BETWEEN HEPATITIS HCV-MONOINFECTED AND HCV-HIV-COINFECTED PATIENTS TREATED WITH NEW DAA-BASED THERAPIES M.L. Montes 1 , A. Ahumada 2 , T. Aldamiz 3 , A. Olveira 4 , L. Bailón 1 , J. García-Samaniego 4 , J. Berenguer 3 , D. Perez-Valderas 2 , V. Moreno 1 , P. Miralles 3 , P. Castillo 4 , D. Rincón 2 , E. Valencia 1 , M. Romero 4 , J. de Quirós L.B. Carlos 3 , M.V. Catalina 2 , A. Garcia 4 , F. Parras 3 , A. Matilla 2 , M. Abadía 4 , M. Rico 1 , L. Martin-Carbonero 1 . 1 Unidad VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, IdiPaz; 2 Unidad de Hepatología. Servicio de Digestivo, Hospital General Universitario Gregorio Marañón, CIBERehd.; 3 Unidad VIH, Servicio de Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Instituto Investigación Sanitaria HGM; 4 Unidad de Hepatología, Servicio de Digestivo, Hospital Universitario La Paz. CIBERehd., Madrid, Spain E-mail: dra_montes@yahoo.es Background and Aims: Our aim was to compare HCV mono (HCV) and HIV-coinfected (HIV/HCV) individuals treated with DAA in two large cohorts in Madrid. Methods: Prospective analysis comparing characteristic and outcomes of HCV vs. HIV/HCV patients treated (Apr/15–Oct/15) at our centers. Results: 1,240 HCV and 490 HIV/HCV individuals were treated (Table 1). HIV/HCV individuals were younger (mean age: 51.4 vs. 58.4 years), more frequently male (76.5% vs. 55.2%) and were more commonly infected with genotypes 1a (36.7% vs. 17.2%), 3 (14.7% vs. 6.6%) and 4 (23.5% vs. 4.6%). No significant differences were found in the child-Pugh category, liver stiffness (LS) and HCV-RNA level. LS > 14 Kpa were observed in 42.3% of the HCV and in 48% of the HIV/HCV individuals. DAA-regimens differed between HCV and HIV/HCV. The main difference was that Abbvie-3D regimen was most commonly used in HCV individuals with 1a genotype (36% vs. 15%; p <0.001). Data of SVR at W12 was already available only in 266 HCV and 98 HIV/HCV individuals (21%): 96.6% for HCV vs. 95.5% for HIV/HCV. Updated data will be giving during the conference. Conclusions: Approximately half of the patients treated with DAA- regimens had advanced liver disease. No significant differences between HCV and HIV/HCV were seen in severity of liver disease, although HIV/HCV were ten years younger. Significant differences between groups were also found in gender and genotype distribution. The type of DAA-regimens according to genotype was similar between both groups, except in genotype 1a, in with the Abbvie-3D regimenwas more frequently used in HCV than HIV/HCV individuals. HCV- monoinfected HCV-HIV- coinfected p N 1,240 490 Male 684(55.2) 375(76.5) <0.001 Age (ys) 58.4(52.3–67.1) 51.4(48.2–54.3) <0.001 Child-Pugh categories A 427(81.5) 187(80.3) 0.9 B 90(17.2) 42(18) C 7(1.3) 4(1.7) LS > 14 (kPA) – n (%) 478(42.3) 232(48) 0.16 Genotype 1a 213(17.2) 180(36.7) <0.001 1b 836(67.4) 78(15.9) 2 19(1.5) 5(1) 3 82(6.6) 72(14.7) 4 57(4.6) 115(23.5) Other/mixed 38(3.1) 40(8.2) HCV-RNA (log IU/mL) 6.1(5.7–6.6) 6.2(5.8–6.6) 0.1 DAA-regimens SOF/LED 576(46.5) 289(59) <0.001 3D or 2D 485(39.1) 90(18.4) SOF/DCV 80(6.5) 76(15.5) SOF/SIM 59(4.8) 22(4.5) Other 40(3.2) 13(2.7) Ribavirin 459(37.0) 172(35.1) 0.5 Values are given as n (%) or median (interquartile range). LS: Liver stiffness. SOF: sofosbuvir, LED: ledipasvir, 3D: Ombitasvir/ritonavir/ paritaprevir + dasabuvir 2D: Ombitasvir/ritonavir/paritaprevir, DCV: daclatasvir, SIM: simeprevir. SAT-207 EFFICACY AND TOLERABILITY OF INTERFERON-FREE ANTIVIRAL THERAPY IN KIDNEY TRANSPLANT (KT) RECIPIENTS WITH CHRONIC HEPATITIS C: REAL-LIFE DATA FROM THE SPANISH NATIONAL REGISTRY (HEPA-C) M.-C. Londoño 1 , I. Fernández 2 , R. Muñoz-Gómez 2 , J.-M. Pascasio 3 , C. Baliellas 4 , N. Polanco 5 , N. Esforzado 6 , M. Prieto 7 , L. Castells 8 , J. Crespo 9 , J.-L. Calleja 10 , F. Gea 11 , X. Forns 12 . 1 Liver Unit, Hospital Clinic Barcelona, Barcelona; 2 Digestive Disease Service, Hospital 12 de Octubre, Madrid; 3 Digestive Diseases, IBIS, CIBEREHD, Hospital Universitario Virgen del Rocío, Sevilla; 4 Digestive Disease Service, Liver Transplant Unit, Hospital Universitari de Bellvitge, Barcelona; 5 Nephrology Department, Hospital 12 de Octubre, Madrid; 6 Nephrology Department, Hospital Clinic Barcelona, Barcelona; 7 Liver Unit, Digestive Medicine Service, Hospital Universitari i Politecnic La Fe, Valencia; 8 Internal Medicine-Hepatology Service, Hospital Vall d’ Hebron, Barcelona; 9 Digestive Disease Service, Hospital Universitario Marques de Valdecilla, Santander; 10 Digestive Diseases Service, Hospital Puerta de Hierro de Majadahonda; 11 Digestive disease department, Hospital Ramon y Cajal, Madrid; 12 Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain E-mail: mlondono@clinic.ub.es Background and Aims: Approximately 5% to 15% of KT recipients have chronic hepatitis C. This entails significant morbidity and poorer graft outcomes. In the interferon (INF) era, viral eradication was limited due to the high risk of allograft dysfunction with the use of INF. The development of direct acting antiviral agents (DAA) with better efficacy and safety profiles has completely changed the scenario. The aims of this study were: 1) to evaluate efficacy and tolerability of DAA combinations in KT recipients and 2) to determine the impact of therapy on renal function and immunosuppression (IS) trough levels. Methods: Hepa-C is a Spanish national registry for the use of DAAs in patients with chronic hepatitis C. Data are prospectively included into the registry and monitored for quality. Clinical, analytical and virological data are collected. Results: 74 KT recipients with a mean age of 54 years (27–74) were included. The majority of the patients were male (62%), infected with genotype 1 (85%) and had advanced fibrosis (F3: 15% POSTER PRESENTATIONS S793 Journal of Hepatology 2016 vol. 64 | S631–S832